Search results
Results from the WOW.Com Content Network
Advanced pancreatic cancer is a difficult-to-treat cancer with the lowest survival rates among all cancer types. ... of metastatic breast cancer. In October 2012, ABRAXANE was approved by the U.S ...
In 2010, Abraxis was acquired by Celgene, which now markets Abraxane. [15] Total revenue from the sales of Abraxane for 2009 were $314.5 million. [16] In 2013, Abraxane was FDA approved for the treatment of pancreatic cancer. [17] In 2014, Abraxane's sales were $848 million, 31 percent year-over-year increase. [18]
Paclitaxel, sold under the brand name Taxol among others, is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. [11] It is administered by intravenous injection. [11] There is also an albumin-bound formulation. [11]
Under this new name, seventy-four trials were undertaken to test Abraxane against various cancer targets. [8] The drug, which was approved by the FDA in 2005, was the subject of a litigation (Elan Pharma v. Abraxis BioScience) for patent infringement. [9] In 2008, Abraxis was ordered to pay $55.2 million to Elan. [9]
ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a ...
Metastatic breast cancer can be treated, sometimes for many years, but it cannot be cured. [2] Distant metastases are the cause of about 90% of deaths due to breast cancer. [3] Breast cancer can metastasize anywhere in body but primarily metastasizes to the bone, lungs, regional lymph nodes, liver and brain, with the most common site being the ...
ABRAXANE ® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene ...
The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]